-DOCSTART- -X- O
Recent -X- _ O
evidence -X- _ O
suggests -X- _ O
that -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
are -X- _ O
able -X- _ O
to -X- _ O
tolerate -X- _ O
lower -X- _ O
levels -X- _ O
of -X- _ O
haemoglobin -X- _ O
than -X- _ O
was -X- _ O
previously -X- _ O
believed. -X- _ O
It -X- _ O
is -X- _ O
our -X- _ O
goal -X- _ O
to -X- _ O
show -X- _ O
that -X- _ O
transfusing -X- _ O
to -X- _ O
a -X- _ O
level -X- _ O
of -X- _ O
100 -X- _ O
g -X- _ O
/ -X- _ O
l -X- _ O
does -X- _ O
not -X- _ B-Outcome
improve -X- _ I-Outcome
mortality -X- _ I-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
clinically -X- _ I-Outcome
important -X- _ I-Outcome
outcomes -X- _ I-Outcome
in -X- _ O
a -X- _ O
critical -X- _ O
care -X- _ O
setting. -X- _ O
Although -X- _ O
many -X- _ O
questions -X- _ O
remain -X- _ O
, -X- _ O
many -X- _ O
laboratory -X- _ O
and -X- _ O
clinical -X- _ O
studies -X- _ O
, -X- _ O
including -X- _ O
a -X- _ O
recent -X- _ O
randomized -X- _ O
controlled -X- _ O
trial -X- _ O
( -X- _ O
RCT -X- _ O
) -X- _ O
, -X- _ O
have -X- _ O
established -X- _ O
that -X- _ O
transfusing -X- _ B-Intervention
to -X- _ I-Intervention
normal -X- _ I-Intervention
haemoglobin -X- _ I-Intervention
concentrations -X- _ I-Intervention
does -X- _ O
not -X- _ B-Outcome
improve -X- _ I-Outcome
organ -X- _ I-Outcome
failure -X- _ I-Outcome
and -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ O
the -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
patient. -X- _ I-Patient
In -X- _ O
addition -X- _ O
, -X- _ O
a -X- _ O
restrictive -X- _ O
transfusion -X- _ O
strategy -X- _ O
will -X- _ O
reduce -X- _ O
exposure -X- _ O
to -X- _ O
allogeneic -X- _ O
transfusions -X- _ O
, -X- _ O
result -X- _ O
in -X- _ O
more -X- _ O
efficient -X- _ O
use -X- _ O
of -X- _ O
red -X- _ O
blood -X- _ O
cells -X- _ O
( -X- _ O
RBCs -X- _ O
) -X- _ O
, -X- _ O
save -X- _ O
blood -X- _ O
overall -X- _ O
, -X- _ O
and -X- _ O
decrease -X- _ O
health -X- _ O
care -X- _ O
costs -X- _ O
. -X- _ O

